摘要
目的:研讨小剂量干扰素联合阿糖胞苷治疗慢性粒细胞白血病的临床价值。方法:将我院2015年8月至2018年1月收治的80例慢性粒细胞白血病患者作为研究对象,按照随机数字表法分为对照组和研究组,每组40例,对照组接受羟基脲治疗,研究组在对照组治疗基础上接受小剂量干扰素联合阿糖胞苷治疗,比较两组患者治疗效果。结果:研究组治疗总有效率(95%)明显高于对照组(80%)(P<0.05);随访患者1年,研究组生存率(52.50%)明显高于对照组(32.50%)(P<0.05);研究组不良反应总发生率(7.50%)与对照组(10%)间的差异无统计学意义(P>0.05);研究组患者细胞遗传学和血液学缓解时间明显低于对照组(P<0.05)。结论:采用小剂量干扰素联合阿糖胞苷治疗慢性粒细胞白血病,比单用羟基脲治疗效果更为突出,且能够缩短细胞遗传学和血液学缓解时间,延长患者生存时间。
Objective： To investigate clinical value of low-dose interferon combined with Cytarabine in treatment of chronic myeloid leukemia. Methods： 80 patients with chronic myeloid leukemia admitted to our hospital from August 2015 to January 2018 were selected as the research objects, and randomly divided into control group and study group, 40 patients in each group. The control group received Hydroxyurea treatment, while the study group received low-dose interferon combined with Cytarabine on the basis of that of the control group. The therapeutic effects of the two groups were compared. Results： The total effective rate in the study group was 95%, which was significantly higher than that in the control group （80%） （ P 〈0.05）. After 1 year of follow-up, the survival rate of the study group （52.50%） was significantly higher than that of the control group （32.50%） （ P 〈0.05）. There was no significant difference in the total incidence of adverse reactions between the study group （7.50%） and the control group （10%） （ P 〉0.05）.The cytogenetics and hematologic remission time were significantly lower in the study group than in the control group （ P 〈0.05）. Conclusions： The use of low-dose interferon combined with Cytarabine in the treatment of chronic myeloid leukemia is more effective than Hydroxyurea alone. It can shorten the cytogenetic and hematologic remission time and prolong the survival time of the patients.
作者
耿韦韦
GENG Weiwei(Benxi Central Hospital,Benxi Liaoning 117000,China)
出处
《中国民康医学》
2018年第18期8-9,12,共3页
Medical Journal of Chinese People’s Health
